BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology ...

Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Tharimmune (THAR) received feedback from a Scientific Advice meeting with the European Medicines Agency that included guidance on a planned ...

Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive ...

Tharimmune recently received positive feedback from the European Medicines Agency (EMA) regarding its planned Phase 2 trial for TH104, the company’s lead therapeutic candidate aimed at addressing ...

Big news out of New Jersey this morning as a %Biotech company said it received “positive feedback” from the European ...

2 Common symptoms like fatigue and pruritus (chronic itch) are sometimes misdiagnosed as conditions like atopic dermatitis or psoriasis, causing delays in diagnosis and suitable treatment.

In the three aforementioned studies of epidural delivery of naloxone in combination with an opioid (fentanyl or morphine), the frequency of pruritus was decreased, with no reversal of analgesia noted.

Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...

New research reveals itchiness may be a defense mechanism, with persistent pruritus serving as the skin’s early alarm against ...

Nighttime itch can be annoying and even worrying. Here, 5 possible reasons you're itchy at night, as well as ...

Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by Professor Lei Xiaoguang, in ...